Latest revenue
$9.7M
as of 2026-03-31
Latest net income
$-4.8M
as of 2026-03-31
Net margin
-49.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $111.4M
- Enterprise value
- $111.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.40
- 52-wk low
- $0.64
- Beta
- —
- Shares out
- 107.1M
5-year trend
What this company does
Item 1. Business Overview We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order…
AI summary unavailable — showing raw filing excerpt
Generated from MXCT's filing dated 2026-03-25
Key risks
Item 1A. Risk Factors You should consider carefully the following risks and other information contained in this Annual Report on Form 10-K, including the section of this report captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes. If any of the events contemplated by the following discussion of risks should occur, our business, results of operations, financial condition, and growth prospects could suffer significantly. The risks below are not the only ones we face. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair our business. Risks…
AI summary unavailable — showing raw filing excerpt
Generated from MXCT's filing dated 2026-03-25
Profitability
Gross margin
81.2%
0.6%Operating margin
-157.1%
18.6%Net margin
-135.1%
27.1%Return on equity
-26.0%
30.7%Return on assets
-22.0%
28.5%Leverage
Debt / equity
0.18×
12.3%Debt / assets
15.3%
10.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $9.7M | -7.1% | $-4.8M | +53.7% | -49.2% |
Q4 2025 2025-12-31 | $7.3M | -16.0% | $-9.6M | +9.4% | -131.5% |
Q3 2025 2025-09-30 | $6.8M | -16.4% | $-12.4M | -7.4% | -181.8% |
Q2 2025 2025-06-30 | $8.5M | -18.4% | $-12.4M | -31.8% | -145.3% |
Q1 2025 2025-03-31 | $10.4M | -8.4% | $-10.3M | -7.7% | -98.8% |
Q4 2024 2024-12-31 | $8.7M | — | $-10.6M | — | -121.9% |
Q3 2024 2024-09-30 | $8.2M | +2.0% | $-11.6M | -2.7% | -141.6% |
Q2 2024 2024-06-30 | $10.4M | +15.3% | $-9.4M | +10.8% | -89.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on MXCT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$480.2K
Insider selling
$30.6K
Net activity
+$449.5K
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns MXCT
Institutional value
$23.5M
Total shares held
33.5M
Distinct holders
66
-45 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.8M | $6.2M | -444.1K (-4.8%) | Trimmed |
| 2 | Capricorn Fund Managers Ltd | 8.2M | $5.8M | — | New |
| 3 | Vitruvian Partners LLP | 5.0M | $3.5M | +0 (+0.0%) | No change |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 4.0M | $2.8M | — | New |
| 5 | Peapod Lane Capital LLC | 1.3M | $925.8K | — | New |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 889.2K | $625.1K | — | New |
| 7 | Willis Investment Counsel | 862.8K | $606.1K | +0 (+0.0%) | No change |
| 8 | VANGUARD FIDUCIARY TRUST CO | 643.2K | $452.2K | — | New |
| 9 | DIMENSIONAL FUND ADVISORS LP | 502.6K | $352.9K | -463.9K (-48.0%) | Trimmed |
| 10 | Bank of New York Mellon Corp | 403.9K | $283.8K | +62.5K (+18.3%) | Added |
| 11 | Mink Brook Asset Management LLC | 284.0K | $199.5K | — | New |
| 12 | UBS Group AG | 271.1K | $190.6K | +146.5K (+117.6%) | Added |
| 13 | Voya Investment Management LLC | 256.1K | $179.9K | +234.0K (+1055.9%) | Added |
| 14 | HSBC HOLDINGS PLC | 250.2K | $172.3K | -340.6K (-57.7%) | Trimmed |
| 15 | Rathbones Group PLC | 223.4K | $156.9K | -230.3K (-50.8%) | Trimmed |
| 16 | Nuveen, LLC | 218.5K | $153.5K | +1.2K (+0.5%) | Added |
| 17 | STRS OHIO | 129.5K | $91.0K | +0 (+0.0%) | No change |
| 18 | RHUMBLINE ADVISERS | 122.3K | $85.8K | -15.8K (-11.5%) | Trimmed |
| 19 | Invesco Ltd. | 119.2K | $83.8K | +52.5K (+78.8%) | Added |
| 20 | Callan Family Office, LLC | 113.0K | $79.4K | +57.9K (+105.0%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once MXCT's latest filing finishes processing.